Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2004 2
2005 3
2006 3
2007 2
2008 4
2009 3
2010 7
2011 5
2012 4
2013 3
2014 4
2015 8
2016 8
2017 8
2018 7
2019 4
2020 1
2021 4
2022 6
2023 6
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

79 results

Results by year

Filters applied: . Clear all
Page 1
Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection.
Segal-Maurer S, DeJesus E, Stellbrink HJ, Castagna A, Richmond GJ, Sinclair GI, Siripassorn K, Ruane PJ, Berhe M, Wang H, Margot NA, Dvory-Sobol H, Hyland RH, Brainard DM, Rhee MS, Baeten JM, Molina JM; CAPELLA Study Investigators. Segal-Maurer S, et al. N Engl J Med. 2022 May 12;386(19):1793-1803. doi: 10.1056/NEJMoa2115542. N Engl J Med. 2022. PMID: 35544387 Clinical Trial.
Efficacy and safety of the novel capsid inhibitor lenacapavir to treat multidrug-resistant HIV: week 52 results of a phase 2/3 trial.
Ogbuagu O, Segal-Maurer S, Ratanasuwan W, Avihingsanon A, Brinson C, Workowski K, Antinori A, Yazdanpanah Y, Trottier B, Wang H, Margot N, Dvory-Sobol H, Rhee MS, Baeten JM, Molina JM; GS-US-200-4625 investigators. Ogbuagu O, et al. Lancet HIV. 2023 Aug;10(8):e497-e505. doi: 10.1016/S2352-3018(23)00113-3. Epub 2023 Jul 11. Lancet HIV. 2023. PMID: 37451297 Clinical Trial.
Antibody-like proteins that capture and neutralize SARS-CoV-2.
Kondo T, Iwatani Y, Matsuoka K, Fujino T, Umemoto S, Yokomaku Y, Ishizaki K, Kito S, Sezaki T, Hayashi G, Murakami H. Kondo T, et al. Among authors: yokomaku y. Sci Adv. 2020 Oct 14;6(42):eabd3916. doi: 10.1126/sciadv.abd3916. Print 2020 Oct. Sci Adv. 2020. PMID: 32948512 Free PMC article.
Nanopore Sequencing for Characterization of HIV-1 Recombinant Forms.
Mori M, Ode H, Kubota M, Nakata Y, Kasahara T, Shigemi U, Okazaki R, Matsuda M, Matsuoka K, Sugimoto A, Hachiya A, Imahashi M, Yokomaku Y, Iwatani Y. Mori M, et al. Among authors: yokomaku y. Microbiol Spectr. 2022 Aug 31;10(4):e0150722. doi: 10.1128/spectrum.01507-22. Epub 2022 Jul 27. Microbiol Spectr. 2022. PMID: 35894615 Free PMC article.
The HIV care cascade: Japanese perspectives.
Iwamoto A, Taira R, Yokomaku Y, Koibuchi T, Rahman M, Izumi Y, Tadokoro K. Iwamoto A, et al. Among authors: yokomaku y. PLoS One. 2017 Mar 20;12(3):e0174360. doi: 10.1371/journal.pone.0174360. eCollection 2017. PLoS One. 2017. PMID: 28319197 Free PMC article.
Molecular epidemiological features of SARS-CoV-2 in Japan, 2020-1.
Ode H, Nakata Y, Nagashima M, Hayashi M, Yamazaki T, Asakura H, Suzuki J, Kubota M, Matsuoka K, Matsuda M, Mori M, Sugimoto A, Imahashi M, Yokomaku Y, Sadamasu K, Iwatani Y. Ode H, et al. Among authors: yokomaku y. Virus Evol. 2022 Apr 7;8(1):veac034. doi: 10.1093/ve/veac034. eCollection 2022. Virus Evol. 2022. PMID: 35478716 Free PMC article.
Virological outcomes of various first-line ART regimens in patients harbouring HIV-1 E157Q integrase polymorphism: a multicentre retrospective study.
Uno S, Gatanaga H, Hayashida T, Imahashi M, Minami R, Koga M, Samukawa S, Watanabe D, Fujii T, Tateyama M, Nakamura H, Matsushita S, Yoshino Y, Endo T, Horiba M, Taniguchi T, Moro H, Igari H, Yoshida S, Teshima T, Nakajima H, Nishizawa M, Yokomaku Y, Iwatani Y, Hachiya A, Kato S, Hasegawa N, Yoshimura K, Sugiura W, Kikuchi T. Uno S, et al. Among authors: yokomaku y. J Antimicrob Chemother. 2023 Dec 1;78(12):2859-2868. doi: 10.1093/jac/dkad319. J Antimicrob Chemother. 2023. PMID: 37856677
Structural Insights into HIV-1 Vif-APOBEC3F Interaction.
Nakashima M, Ode H, Kawamura T, Kitamura S, Naganawa Y, Awazu H, Tsuzuki S, Matsuoka K, Nemoto M, Hachiya A, Sugiura W, Yokomaku Y, Watanabe N, Iwatani Y. Nakashima M, et al. Among authors: yokomaku y. J Virol. 2015 Nov 4;90(2):1034-47. doi: 10.1128/JVI.02369-15. Print 2016 Jan 15. J Virol. 2015. PMID: 26537685 Free PMC article.
Association of demographics, HCV co-infection, HIV-1 subtypes and genetic clustering with late HIV diagnosis: a retrospective analysis from the Japanese Drug Resistance HIV-1 Surveillance Network.
Otani M, Shiino T, Hachiya A, Gatanaga H, Watanabe D, Minami R, Nishizawa M, Teshima T, Yoshida S, Ito T, Hayashida T, Koga M, Nagashima M, Sadamasu K, Kondo M, Kato S, Uno S, Taniguchi T, Igari H, Samukawa S, Nakajima H, Yoshino Y, Horiba M, Moro H, Watanabe T, Imahashi M, Yokomaku Y, Mori H, Fujii T, Takada K, Nakamura A, Nakamura H, Tateyama M, Matsushita S, Yoshimura K, Sugiura W, Matano T, Kikuchi T; Japanese Drug Resistance HIV-1 Surveillance Network. Otani M, et al. Among authors: yokomaku y. J Int AIDS Soc. 2023 May;26(5):e26086. doi: 10.1002/jia2.26086. J Int AIDS Soc. 2023. PMID: 37221951 Free PMC article.
Cellular APOBEC3A deaminase drives mutations in the SARS-CoV-2 genome.
Nakata Y, Ode H, Kubota M, Kasahara T, Matsuoka K, Sugimoto A, Imahashi M, Yokomaku Y, Iwatani Y. Nakata Y, et al. Among authors: yokomaku y. Nucleic Acids Res. 2023 Jan 25;51(2):783-795. doi: 10.1093/nar/gkac1238. Nucleic Acids Res. 2023. PMID: 36610792 Free PMC article.
79 results